Bhaskar Gundabolu, MD
Endocrinology, Diabetes & Metabolism · Toledo, OHNPI 1346458767
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $400,794 of the $470,720 with a category attached, or 85.1%. 27 manufacturers reported payments, led by Lilly USA, LLC at 34.3% of the total. Reporting peaked in 2019 at $288,859 and has fallen 100.0% since, to $69 in 2025. Among endocrinology, diabetes & metabolism clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 887 payments — averaging $530.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$162K
- Amgen$125K
- AstraZeneca$92K
- Novo Nordisk$60K
- Johnson & Johnson$16K
- Abbott$10K
- plus $5K from 21 others
What the payments were for
- Consulting fees$3,7501%
- Speaking & faculty fees$400,79485%
- Travel & lodging$53,73411%
- Food & beverage$12,3723%
- Education$710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 387 | $161,603 |
| Amgen(2 entities) | 172 | $125,176 |
| AstraZeneca(2 entities) | 137 | $92,357 |
| Novo Nordisk | 69 | $60,362 |
| Johnson & Johnson | 29 | $16,295 |
| Abbott | 13 | $10,046 |
| Merck | 9 | $3,834 |
| Dexcom, Inc. | 15 | $237 |
| Medtronic | 13 | $165 |
| Tandem Diabetes Care, Inc. | 7 | $79 |
| Sanofi-aventis U.S. LLC | 5 | $71 |
| Boehringer Ingelheim | 3 | $65 |
| Shire North American Group Inc | 4 | $61 |
| Regeneron Healthcare Solutions, Inc. | 3 | $49 |
| Radius Health, Inc. | 3 | $47 |
| Mannkind Corporation | 3 | $45 |
| Amarin Pharma, Inc. | 2 | $40 |
| Valeritas, Inc. | 2 | $29 |
| Insulet Corporation | 2 | $26 |
| AbbVie | 1 | $25 |
| Pfizer | 2 | $24 |
| Antares Pharma, Inc. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| BETA Bionics, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$470,720 in reported general payments places this provider in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StrensiqAsfotase Alfa | 138 | $14,063,791 |
| OzempicSemaglutide | 267 | $422,602 |
| TrulicityDulaglutide | 229 | $399,716 |
| JardianceEmpagliflozin | 259 | $327,238 |
| MounjaroTirzepatide | 195 | $279,247 |
| FarxigaDapagliflozin Propanediol | 210 | $229,144 |
| Tresiba Flextouch U-200Insulin Degludec | 106 | $129,930 |
| Tresiba Flextouch U-100Insulin Degludec | 91 | $88,277 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 64 | $79,646 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 41 | $73,607 |
| Bydureon BciseExenatide Microspheres | 39 | $68,144 |
| JanuviaSitagliptin Phosphate | 70 | $64,782 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 85 | $54,574 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 79 | $54,375 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 53 | $53,700 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaStrensiq, Farxiga | $92,357 | $14,292,935348 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $161,603 | $678,963424 claims |
| Novo NordiskOzempic, Rybelsus | $60,362 | $463,117289 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $65 | $374,972297 claims |
| MerckJanuvia | $3,834 | $64,78270 claims |
| Johnson & JohnsonInvokana | $16,295 | $28,13717 claims |
| AbbVieSynthroid, Restasis | $25 | $17,218230 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $15,3511,162 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $71 | $10,44215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Toledo
- Elena ChristofidesColumbus$2.3M
- Kevin PantaloneCleveland$1.2M
- John PaesWesterville$671K
- Samuel AndersonColumbus$556K
- Nelson WattsCincinnati$346K
- Baker MachhadiehHamilton$304K
- Brian BurtchMentor$264K
- Allan KennedyCleveland$245K
- Shawn PeavieCincinnati$201K
- Amanda DenneyCincinnati$183K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.